DOI: 10.4049/jimmunol.164.3.1243. Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells

Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells

10.4049/jimmunol.164.3.1243

Crossref journal-article

Oxford University Press (OUP)

The Journal of Immunology (286)

Abstract

AbstractPresentation of MHC class I-restricted peptides by dendritic cells (DCs) can elicit vigorous antigen-specific CTL responses in vivo. It is well established, however, that T cell help can augment CTL function, raising the question of how best to present tumor-associated MHC class I epitopes to induce effective tumor immunity. To this end, we have examined the role of MHC class II peptide-complexes present on the immunizing DCs in a murine melanoma model. To present MHC class I- and II-restricted Ags reliably on the same cell, we retrovirally transduced bone marrow-derived DCs with the model Ag OVA encoding well-defined class I- and II-restricted epitopes. The importance of CD4+ T cells activated by the immunizing DCs in this model is demonstrated by the following findings: 1) transduced DCs presenting class I and class II epitopes are more efficient than class I peptide-pulsed DCs; 2) MHC class II-deficient DCs fail to induce tumor protection; 3) CD4+ T cell depletion abolishes induction of tumor protection; and 4) DCs presenting bovine serum Ags are more effective in establishing tumor immunity than DCs cultured in syngeneic serum. When MHC class II-deficient DCs were directly activated via their CD40 receptor, we indeed observed a moderate elevation of OVA-specific CTL activity. However, this increase in CTL activity was not sufficient to induce in vivo tumor rejection. Thus, our results demonstrate the potency of genetically modified DCs that express both MHC class I and II epitopes, but caution against the use of DCs presenting only the former.

Bibliography

Schnell, S., Young, J. W., Houghton, A. N., & Sadelain, M. (2000). Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells. The Journal of Immunology, 164(3), 1243â1250.

Authors 4

Stefan Schnell (first)
James W. Young (additional)
Alan N. Houghton (additional)
Michel Sadelain (additional)

References 42 Referenced 52

Dates

Type	When
Created	11 years, 4 months ago (April 21, 2014, 6:48 p.m.)
Deposited	8 months ago (Jan. 2, 2025, 12:24 p.m.)
Indexed	5 months ago (March 30, 2025, 10:46 a.m.)
Issued	25 years, 7 months ago (Feb. 1, 2000)
Published	25 years, 7 months ago (Feb. 1, 2000)
Published Print	25 years, 7 months ago (Feb. 1, 2000)

Funders 0

None

BibTeX

@article{Schnell_2000, title={Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells}, volume={164}, ISSN={1550-6606}, url={http://dx.doi.org/10.4049/jimmunol.164.3.1243}, DOI={10.4049/jimmunol.164.3.1243}, number={3}, journal={The Journal of Immunology}, publisher={Oxford University Press (OUP)}, author={Schnell, Stefan and Young, James W. and Houghton, Alan N. and Sadelain, Michel}, year={2000}, month=feb, pages={1243–1250} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        3,
        30
      ]
    ],
    "date-time": "2025-03-30T14:46:18Z",
    "timestamp": 1743345978756,
    "version": "3.32.0"
  },
  "reference-count": 42,
  "publisher": "Oxford University Press (OUP)",
  "issue": "3",
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2000,
        2,
        1
      ]
    ]
  },
  "abstract": "<jats:title>Abstract</jats:title><jats:p>Presentation of MHC class I-restricted peptides by dendritic cells (DCs) can elicit vigorous antigen-specific CTL responses in vivo. It is well established, however, that T cell help can augment CTL function, raising the question of how best to present tumor-associated MHC class I epitopes to induce effective tumor immunity. To this end, we have examined the role of MHC class II peptide-complexes present on the immunizing DCs in a murine melanoma model. To present MHC class I- and II-restricted Ags reliably on the same cell, we retrovirally transduced bone marrow-derived DCs with the model Ag OVA encoding well-defined class I- and II-restricted epitopes. The importance of CD4+ T cells activated by the immunizing DCs in this model is demonstrated by the following findings: 1) transduced DCs presenting class I and class II epitopes are more efficient than class I peptide-pulsed DCs; 2) MHC class II-deficient DCs fail to induce tumor protection; 3) CD4+ T cell depletion abolishes induction of tumor protection; and 4) DCs presenting bovine serum Ags are more effective in establishing tumor immunity than DCs cultured in syngeneic serum. When MHC class II-deficient DCs were directly activated via their CD40 receptor, we indeed observed a moderate elevation of OVA-specific CTL activity. However, this increase in CTL activity was not sufficient to induce in vivo tumor rejection. Thus, our results demonstrate the potency of genetically modified DCs that express both MHC class I and II epitopes, but caution against the use of DCs presenting only the former.</jats:p>",
  "DOI": "10.4049/jimmunol.164.3.1243",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2014,
        4,
        21
      ]
    ],
    "date-time": "2014-04-21T22:48:20Z",
    "timestamp": 1398120500000
  },
  "page": "1243-1250",
  "source": "Crossref",
  "is-referenced-by-count": 52,
  "title": "Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells",
  "prefix": "10.1093",
  "volume": "164",
  "author": [
    {
      "given": "Stefan",
      "family": "Schnell",
      "sequence": "first",
      "affiliation": [
        {
          "name": "*Human Genetics and"
        },
        {
          "name": "\u2021Immunology Program, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021"
        }
      ]
    },
    {
      "given": "James W.",
      "family": "Young",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "\u2020Medicine, and"
        }
      ]
    },
    {
      "given": "Alan N.",
      "family": "Houghton",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "\u2020Medicine, and"
        },
        {
          "name": "\u2021Immunology Program, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021"
        }
      ]
    },
    {
      "given": "Michel",
      "family": "Sadelain",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "*Human Genetics and"
        },
        {
          "name": "\u2021Immunology Program, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021"
        }
      ]
    }
  ],
  "member": "286",
  "reference": [
    {
      "key": "2023010117303680000_R1",
      "doi-asserted-by": "crossref",
      "unstructured": "Banchereau, J., R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature\u2008392: 245",
      "DOI": "10.1038/32588"
    },
    {
      "key": "2023010117303680000_R2",
      "doi-asserted-by": "crossref",
      "unstructured": "Pardoll, D. M.. 1998. Cancer vaccines. Nat. Med.\u20084: 525",
      "DOI": "10.1038/nm0598supp-525"
    },
    {
      "key": "2023010117303680000_R3",
      "doi-asserted-by": "crossref",
      "unstructured": "Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, et al\u20081995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med.\u20081: 1297",
      "DOI": "10.1038/nm1295-1297"
    },
    {
      "key": "2023010117303680000_R4",
      "doi-asserted-by": "crossref",
      "unstructured": "Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med.\u2008183: 283",
      "DOI": "10.1084/jem.183.1.283"
    },
    {
      "key": "2023010117303680000_R5",
      "doi-asserted-by": "crossref",
      "unstructured": "Porgador, A., D. Snyder, E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol.\u2008156: 2918",
      "DOI": "10.4049/jimmunol.156.8.2918"
    },
    {
      "key": "2023010117303680000_R6",
      "doi-asserted-by": "crossref",
      "unstructured": "Young, J. W., R. M. Steinman. 1990. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J. Exp. Med.\u2008171: 1315",
      "DOI": "10.1084/jem.171.4.1315"
    },
    {
      "key": "2023010117303680000_R7",
      "doi-asserted-by": "crossref",
      "unstructured": "Sigal, L. J., H. Reiser, K. L. Rock. 1998. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J. Immunol.\u2008161: 2740",
      "DOI": "10.4049/jimmunol.161.6.2740"
    },
    {
      "key": "2023010117303680000_R8",
      "doi-asserted-by": "crossref",
      "unstructured": "Keene, J. A., J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med.\u2008155: 768",
      "DOI": "10.1084/jem.155.3.768"
    },
    {
      "key": "2023010117303680000_R9",
      "doi-asserted-by": "crossref",
      "unstructured": "Bennett, S. R., F. R. Carbone, F. Karamalis, J. F. Miller, W. R. Heath. 1997. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med.\u2008186: 65",
      "DOI": "10.1084/jem.186.1.65"
    },
    {
      "key": "2023010117303680000_R10",
      "doi-asserted-by": "crossref",
      "unstructured": "Kern, D. E., J. P. Klarnet, M. C. Jensen, P. D. Greenberg. 1986. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol.\u2008136: 4303",
      "DOI": "10.4049/jimmunol.136.11.4303"
    },
    {
      "key": "2023010117303680000_R11",
      "doi-asserted-by": "crossref",
      "unstructured": "Zitvogel, L., P. D. Robbins, W. J. Storkus, M. R. Clarke, M. J. Maeurer, R. L. Campbell, C. G. Davis, H. Tahara, R. D. Schreiber, M. T. Lotze. 1996. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol.\u200826: 1335",
      "DOI": "10.1002/eji.1830260624"
    },
    {
      "key": "2023010117303680000_R12",
      "doi-asserted-by": "crossref",
      "unstructured": "Toes, R. E., F. Ossendorp, R. Offringa, C. J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med.\u2008189: 753",
      "DOI": "10.1084/jem.189.5.753"
    },
    {
      "key": "2023010117303680000_R13",
      "doi-asserted-by": "crossref",
      "unstructured": "Rock, K. L., S. Gamble, L. Rothstein. 1990. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science\u2008249: 918",
      "DOI": "10.1126/science.2392683"
    },
    {
      "key": "2023010117303680000_R14",
      "doi-asserted-by": "crossref",
      "unstructured": "Shimonkevitz, R., S. Colon, J. W. Kappler, P. Marrack, H. M. Grey. 1984. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol.\u2008133: 2067",
      "DOI": "10.4049/jimmunol.133.4.2067"
    },
    {
      "key": "2023010117303680000_R15",
      "doi-asserted-by": "crossref",
      "unstructured": "Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature\u2008393: 478",
      "DOI": "10.1038/30996"
    },
    {
      "key": "2023010117303680000_R16",
      "doi-asserted-by": "crossref",
      "unstructured": "Ridge, J. P., F. Di Rosa, P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature\u2008393: 474",
      "DOI": "10.1038/30989"
    },
    {
      "key": "2023010117303680000_R17",
      "doi-asserted-by": "crossref",
      "unstructured": "Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature\u2008393: 480",
      "DOI": "10.1038/31002"
    },
    {
      "key": "2023010117303680000_R18",
      "doi-asserted-by": "crossref",
      "unstructured": "Grusby, M. J., R. S. Johnson, V. E. Papaioannou, L. H. Glimcher. 1991. Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science\u2008253: 1417",
      "DOI": "10.1126/science.1910207"
    },
    {
      "key": "2023010117303680000_R19",
      "doi-asserted-by": "crossref",
      "unstructured": "Falo, L. D., Jr., M. Kovacsovics-Bankowski, K. Thompson, and K. L. Rock. 1995. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1:649.",
      "DOI": "10.1038/nm0795-649"
    },
    {
      "key": "2023010117303680000_R20",
      "doi-asserted-by": "crossref",
      "unstructured": "Riviere, I., K. Brose, R. C. Mulligan. 1995. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA\u200892: 6733",
      "DOI": "10.1073/pnas.92.15.6733"
    },
    {
      "key": "2023010117303680000_R21",
      "doi-asserted-by": "crossref",
      "unstructured": "Gallardo, H. F., C. Tan, D. Ory, M. Sadelain. 1997. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood\u200890: 952",
      "DOI": "10.1182/blood.V90.3.952"
    },
    {
      "key": "2023010117303680000_R22",
      "doi-asserted-by": "crossref",
      "unstructured": "Markowitz, D., S. Goff, A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol.\u200862: 1120",
      "DOI": "10.1128/jvi.62.4.1120-1124.1988"
    },
    {
      "key": "2023010117303680000_R23",
      "doi-asserted-by": "crossref",
      "unstructured": "Riviere, I., M. Sadelain. 1997. Methods for the construction of retroviral vectors and the generation of high-titer producers. In Methods in Molecular Medicine, Vol. Gene Therapy Protocols. P. Robbins, ed. Humana Press, Totowa pp.\u2008: 59-78.",
      "DOI": "10.1385/0-89603-484-4:59"
    },
    {
      "key": "2023010117303680000_R24",
      "doi-asserted-by": "crossref",
      "unstructured": "Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med.\u2008176: 1693",
      "DOI": "10.1084/jem.176.6.1693"
    },
    {
      "key": "2023010117303680000_R25",
      "doi-asserted-by": "crossref",
      "unstructured": "Heath, A. W., W. W. Wu, M. C. Howard. 1994. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur. J. Immunol.\u200824: 1828",
      "DOI": "10.1002/eji.1830240816"
    },
    {
      "key": "2023010117303680000_R26",
      "unstructured": "Lehmann, E. L.. 1975. Statistical methods based on ranks Holden-Day, Boca Raton."
    },
    {
      "key": "2023010117303680000_R27",
      "doi-asserted-by": "crossref",
      "unstructured": "Shastri, N., F. Gonzales. 1993. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J. Immunol.\u2008150: 2724",
      "DOI": "10.4049/jimmunol.150.7.2724"
    },
    {
      "key": "2023010117303680000_R28",
      "doi-asserted-by": "crossref",
      "unstructured": "Moore, M. W., F. R. Carbone, M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell\u200854: 777",
      "DOI": "10.1016/S0092-8674(88)91043-4"
    },
    {
      "key": "2023010117303680000_R29",
      "doi-asserted-by": "crossref",
      "unstructured": "Sanderson, S., K. Frauwirth, N. Shastri. 1995. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl. Acad. Sci. USA\u200892: 7217",
      "DOI": "10.1073/pnas.92.16.7217"
    },
    {
      "key": "2023010117303680000_R30",
      "doi-asserted-by": "crossref",
      "unstructured": "Stuhler, G., A. Zobywalski, F. Grunebach, P. Brossart, V. L. Reichardt, H. Barth, S. Stevanovic, W. Brugger, L. Kanz, S. F. Schlossman. 1999. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. Proc. Natl. Acad. Sci. USA\u200896: 1532",
      "DOI": "10.1073/pnas.96.4.1532"
    },
    {
      "key": "2023010117303680000_R31",
      "doi-asserted-by": "crossref",
      "unstructured": "van Elsas, A., A. A. Hurwitz, J. P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med.\u2008190: 355",
      "DOI": "10.1084/jem.190.3.355"
    },
    {
      "key": "2023010117303680000_R32",
      "doi-asserted-by": "crossref",
      "unstructured": "Zhang, W., L. He, Z. Yuan, Z. Xie, J. Wang, H. Hamada, X. Cao. 1999. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum. Gene Ther.\u200810: 1151",
      "DOI": "10.1089/10430349950018148"
    },
    {
      "key": "2023010117303680000_R33",
      "unstructured": "Mackey, M. F., J. R. Gunn, P. P. Ting, H. Kikutani, G. Dranoff, R. J. Noelle, R. J. Barth, Jr. 1997. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res.\u200857: 2569"
    },
    {
      "key": "2023010117303680000_R34",
      "doi-asserted-by": "crossref",
      "unstructured": "Mackey, M. F., J. R. Gunn, C. Maliszewsky, H. Kikutani, R. J. Noelle, R. J. Barth, Jr. 1998. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol.\u2008161: 2094",
      "DOI": "10.4049/jimmunol.161.5.2094"
    },
    {
      "key": "2023010117303680000_R35",
      "doi-asserted-by": "crossref",
      "unstructured": "Labeur, M. S., B. Roters, B. Pers, A. Mehling, T. A. Luger, T. Schwarz, S. Grabbe. 1999. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol.\u2008162: 168",
      "DOI": "10.4049/jimmunol.162.1.168"
    },
    {
      "key": "2023010117303680000_R36",
      "doi-asserted-by": "crossref",
      "unstructured": "French, R. R., H. T. Chan, A. L. Tutt, M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med.\u20085: 548",
      "DOI": "10.1038/8426"
    },
    {
      "key": "2023010117303680000_R37",
      "doi-asserted-by": "crossref",
      "unstructured": "Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med.\u20085: 774",
      "DOI": "10.1038/10495"
    },
    {
      "key": "2023010117303680000_R38",
      "doi-asserted-by": "crossref",
      "unstructured": "Hermans, I. F., D. S. Ritchie, A. Daish, J. Yang, M. R. Kehry, F. Ronchese. 1999. Impaired ability of MHC class II\u2212/\u2212 dendritic cells to provide tumor protection is rescued by CD40 ligation. J. Immunol.\u2008163: 77",
      "DOI": "10.4049/jimmunol.163.1.77"
    },
    {
      "key": "2023010117303680000_R39",
      "doi-asserted-by": "crossref",
      "unstructured": "Bachmann, M. F., B. R. Wong, R. Josien, R. M. Steinman, A. Oxenius, Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med.\u2008189: 1025",
      "DOI": "10.1084/jem.189.7.1025"
    },
    {
      "key": "2023010117303680000_R40",
      "doi-asserted-by": "crossref",
      "unstructured": "Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. [Published erratum appears in 1996 J. Exp. Med. 184:1590.] J. Exp. Med. 184:741.",
      "DOI": "10.1084/jem.184.2.741"
    },
    {
      "key": "2023010117303680000_R41",
      "doi-asserted-by": "crossref",
      "unstructured": "Barlow, A. K., X. He, C. Janeway, Jr. 1998. Exogenously provided peptides of a self-antigen can be processed into forms that are recognized by self-T cells. J. Exp. Med.\u2008187: 1403",
      "DOI": "10.1084/jem.187.9.1403"
    },
    {
      "key": "2023010117303680000_R42",
      "doi-asserted-by": "crossref",
      "unstructured": "Szabolcs, P., H. F. Gallardo, D. H. Ciocon, M. Sadelain, J. W. Young. 1997. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood\u200890: 2160",
      "DOI": "10.1182/blood.V90.6.2160"
    }
  ],
  "container-title": "The Journal of Immunology",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://journals.aai.org/jimmunol/article-pdf/164/3/1243/1115665/1243.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "syndication"
    },
    {
      "URL": "https://journals.aai.org/jimmunol/article-pdf/164/3/1243/1115665/1243.pdf",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2025,
        1,
        2
      ]
    ],
    "date-time": "2025-01-02T17:24:06Z",
    "timestamp": 1735838646000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://journals.aai.org/jimmunol/article/164/3/1243/69555/Retrovirally-Transduced-Mouse-Dendritic-Cells"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2000,
        2,
        1
      ]
    ]
  },
  "references-count": 42,
  "journal-issue": {
    "issue": "3",
    "published-print": {
      "date-parts": [
        [
          2000,
          2,
          1
        ]
      ]
    }
  },
  "URL": "http://dx.doi.org/10.4049/jimmunol.164.3.1243",
  "relation": {},
  "ISSN": [
    "0022-1767",
    "1550-6606"
  ],
  "subject": [],
  "published": {
    "date-parts": [
      [
        2000,
        2,
        1
      ]
    ]
  }
}